ImmunityBio Long Term Debt

ImmunityBio (IBRX) currently reports a long-term debt of $33M as of March 2026. That compares with $33M in the prior-year period — up 0.2% year over year. Use the charts on this page to explore ImmunityBio's long-term debt history and peer comparisons.

ImmunityBio's long-term debt increased from $33M to $33M — a 0.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunityBio reported $33M in long-term debt as of March 2026. That compares with $33M in the prior-year period — up 0.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $33M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.

ImmunityBio is classified in the Healthcare sector. On long-term debt, it currently shows $33M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.